Comment on Eli Lilly Scores a Win in Diabetes

Eli Lilly Scores a Win in Diabetes

Eli Lilly (NYSE: LLY) just unveiled new data showing that one of its diabetes drugs -- Tradjenta -- doesn't increase the risk of cardiovascular events, including heart attack and stroke. The results could help Tradjenta capture a greater share of the multibillion dollar DPP-4 class of diabetes drugs, so let's learn more about it.In healthy people, the body's pancreas produces insulin that stores or converts glucose, a simple sugar found in carbohydrates and produced in the liver, into energy.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News